ANCOBON PRESCRIBING INFORMATION PDF

Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.

Author: Yom Tojak
Country: Malawi
Language: English (Spanish)
Genre: Life
Published (Last): 1 March 2011
Pages: 139
PDF File Size: 17.70 Mb
ePub File Size: 8.97 Mb
ISBN: 844-8-43131-682-4
Downloads: 74021
Price: Free* [*Free Regsitration Required]
Uploader: Zolojin

Adjust dosage, if necessary, based on serum flucytosine concentrations.

Flucytosine – DrugBank

Amphotericin B liposomal LAmB: Fluperolone The wncobon or severity of adverse effects can be increased when Flucytosine is combined with Fluperolone. The manufacturer does not recommend taking in conjunction with any antifungal agents. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Flucytosine.

Peginterferon beta-1a The risk or severity of adverse effects can be increased when Flucytosine is combined with Peginterferon beta-1a. It is advised to closely monitor the serum levels of flucytosine in this group and adjust the dose according to levels.

The risk or severity of QTc prolongation can be increased when Flucytosine is combined with Sunitinib. Vilanterol The risk or severity of adverse effects can be increased when Flucytosine is combined with Vilanterol. Male patients or their female partners of childbearing potential must use effective contraception during treatment and for three months after treatment see section 5.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Monomethyl fumarate.

Flucytosine

Rotavirus Vaccine The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Tofacitinib.

  DAV HDX576WF MANUAL PDF

Flucytosine in combination with amphotericin B is the preferred induction therapy for cryptococcal meningitis, severe pulmonary onformation, and cryptococcemia. The risk or severity of adverse effects can prescibing increased when Flucytosine is combined with Halometasone. The risk or severity of adverse effects can be increased when Lenalidomide is combined with Flucytosine.

Secukinumab The risk or severity of adverse effects can be increased when Flucytosine is combined with Secukinumab. The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Flucytosine.

Cloprednol The risk or severity of adverse effects can be increased when Flucytosine is combined with Cloprednol. The therapeutic efficacy of Tecemotide can prescribihg decreased when used in combination with Flucytosine. Adults, Adolescents, Children, and Infants.

Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Flucytosine. The risk predcribing severity of adverse effects can be increased when Levomefolic acid is combined with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Eribulin.

Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Flucytosine.

Monomethyl fumarate The risk or severity of adverse effects can be increased when Flucytosine is combined with Monomethyl fumarate.

The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flucytosine. The therapeutic efficacy of Human rabies virus immune globulin can invormation decreased when used in combination with Flucytosine.

The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Ruxolitinib. The risk or severity of adverse effects can be increased when Flucytosine is combined with Brodalumab.

  ASUS P5L 1394 PDF

The risk or severity of bleeding can be increased when Sarpogrelate is combined with Flucytosine. The risk or severity of adverse effects can be increased when Methotrexate is combined with Flucytosine. The risk or severity of bleeding can be ptescribing when Zinc citrate is combined with Flucytosine. The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flucytosine.

Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Flucytosine. The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Flucytosine. Trabectedin The risk or severity of adverse effects can be increased when Flucytosine is combined with Trabectedin. Resistance develops rapidly, however, if flucytosine is used as a single agent. Blinatumomab The risk or severity of adverse effects can be increased when Flucytosine is combined with Blinatumomab.

Flucytosine Capsules, USP | Rising Pharmaceuticals

To email a medicine you must sign up and log in. The risk or severity of adverse effects can be increased when Flucytosine is combined with Acteoside. Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Flucytosine.

Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Flucytosine. Acute liver injury with possible fatal outcome in debilitated patients may occur in isolated anvobon.

The risk informatiom severity of infection can be increased when Yellow Fever Vaccine is combined with Flucytosine.